title: The effect of 4% icodextrin solution on adhesiolysis surgery time at the Hartmann's reversal: a pilot, multicentre, randomized control trial vs lactated Ringer's solution.
abstract: OBJECTIVE
  A pilot randomized controlled clinical multicentre trail was established to compare intraperitoneal 4% icodextrin (ID) solution with lactated Ringer's solution (LRS) on adhesion formation after Hartmann's procedure. The adhesiolysis surgery time during Hartman's reversal was used as a marker of the severity of adhesions.
  
  
  METHODS
  Patients scheduled for Hartmann's resection were randomized at surgery to either of the two study solutions used as an irrigant during the operation and instilled (1000 ml) at the end of surgery. During the reversal procedure, the time for small bowel adhesiolysis was recorded.
  
  
  RESULTS
  On completion of 17 eligible patients, an interim analysis was performed. There were no complications following the use of 4% ID solution. The mean (SD) total adhesiolysis times in patients treated with 4% ID solution and LRS were 30.8 (18.0) min and 47.6 (45.7) min, respectively. The mean reduction of 16.8 min, although greater than expected, was not statistically significant (P = 0.33) because of the large variance in adhesiolysis times. Further statistical analysis showed that to achieve significance for the observed differences and variance, a minimum of 240 patients in each group would be required.
  
  
  CONCLUSIONS
  Icodextrin treatment resulted in a decreasing trend in adhesiolysis time. The use of 4% ID solution in peritonitis patients seemed to be safe. Because of larger than expected variations in adhesiolysis times, this pilot study was underpowered to meet the study end-point and further statistical modelling estimated that significance cannot be reached within a reasonable time scale. Other models should be used to evaluate the efficacy of anti-adhesive agents.
authors.affiliation: Department of Surgery, Päijät-Häme Central Hospital, Lahti, Finland. jyrki.kossi@phsotey.fi
authors.forename: J
authors.initials: J
authors.lastname: Kössi
authors.forename: S
authors.initials: S
authors.lastname: Grönlund
authors.forename: M
authors.initials: M
authors.lastname: Uotila-Nieminen
authors.forename: A
authors.initials: A
authors.lastname: Crowe
authors.forename: A
authors.initials: A
authors.lastname: Knight
authors.forename: U
authors.initials: U
authors.lastname: Keränen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D003125:Colostomy / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D005936:Glucans / Q000627:therapeutic use*; D005947:Glucose / Q000627:therapeutic use*; D006801:Humans; D000077607:Icodextrin; D007552:Isotonic Solutions / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010532:Peritoneal Diseases / Q000188:drug therapy / Q000517:prevention & control / Q000601:surgery*; D000077325:Ringer's Lactate; D007507:Therapeutic Irrigation; D000267:Tissue Adhesions / Q000188:drug therapy / Q000517:prevention & control
chemical_list: D005936:Glucans; D007552:Isotonic Solutions; D000077325:Ringer's Lactate; D000077607:Icodextrin; D005947:Glucose